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Introduction: Ras guanine nucleotide exchange factors (RasGEFs) mediate the activation of the Ras signaling
pathway that is over activated in many human cancers. The RasGRP3, an activator of H-Ras and R-Ras protein exerts
oncogenic effects and the overexpression of the protein is observed in numerous malignant cancer types. Here, we
investigated the putative alteration of expression and potential function of RasGRP3 in the formation and progression
of human breast cancer.
Methods: The RasGRP3 and phosphoRasGRP3 expressions were examined in human invasive ductal adenocarcinoma
derived samples and cell lines (BT-474, JIMT-1, MCF7, SK-BR-3, MDA-MB-453, T-47D) both in mRNA (Q-PCR) and protein
(Western blot; immunohistochemistry) levels. To explore the biological function of the protein, RasGRP3 knockdown
cultures were established. To assess the role of RasGRP3 in the viability of cells, annexin-V/PI staining and MitoProbe™
DilC1 (5) assay were performed. To clarify the function of the protein in cell proliferation and in the development of
chemotherapeutic resistance, CyQuant assay was performed. To observe the RasGRP3 function in tumor formation,
the Severe combined immunodeficiency (SCID) mouse model was used. To investigate the role of the protein in
Ras-related signaling Q-PCR and Western blot experiments were performed.
Results: RasGRP3 expression was elevated in human breast tumor tissue samples as well as in multiple human
breast cancer cell lines. Down-regulation of RasGRP3 expression in breast cancer cells decreased cell proliferation,
induced apoptosis in MCF7 cells, and sensitized T-47D cells to the action of drugs Tamoxifen and trastuzumab
(Herceptin). Gene silencing of RasGRP3 reduced tumor formation in mouse xenografts as well. Inhibition of
RasGRP3 expression also reduced Akt, ERK1/2 and estrogen receptor alpha phosphorylation downstream from
IGF-I insulin like growth factor-I (IGF-I) or epidermal growth factor (EGF) stimulation confirming the functional role
of RasGRP3 in the altered behavior of these cells.
Conclusions: Taken together, our results suggest that the Ras activator RasGRP3 may have a role in the pathological
behavior of breast cancer cells and may constitute a therapeutic target for human breast cancer.
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The activation of Ras family members is conveyed by
specific upstream regulators such as e.g. guanine nucleo-
tide exchange factors (RasGEF) [1]. Reflecting their signifi-
cance, genetic loss of these factors and their functions was
shown to result in similar effects to those induced by the
loss of the Ras proteins themselves [2,3]. In 1998, Ebinu
et al. have introduced a new RasGEF called Ras Guanyl
nucleotide Releasing Peptide or RasGRP [4]. A unique fea-
ture of RasGRPs is the presence of a C1 domain serving
as a binding site for the endogenous signaling molecule
diacylglycerol (DAG) and its exogenous counterparts, the
phorbol esters. As RasGRPs are regulated directly by bind-
ing DAG [5,6], they act as mediators for the a multitude
of receptor-coupled mechanisms (induced e.g. by numer-
ous growth factors) that activate phospholipase C and the
related signal transduction machineries [7,8]. RasGRP3 is
one of the four members of RasGRP family; it was shown
to activate H-Ras and R-Ras [4,9].
The presence and activity of the Ras-related subcellu-
lar processes and the induced biological responses are
one of the key determinants in malignant cell transform-
ation and progression. Efforts to identify the nature and
role of the Ras-related intracellular signalization path-
ways have recently suggested that not only the down-
stream mediators but also the upstream regulators of
Ras might play a role on these mechanisms. In perfect
agreement with this proposal, members of RasGRP fam-
ily are suggested to function as oncogenes in multiple
cancers [10]. Indeed, RasGRP3 is highly expressed in
human Burkitt’s lymphoma, human pre-B-cell leukemia,
and natural killer-like T-cell leukemia. Of further im-
portance, we have recently shown that RasGRP3 is cen-
trally involved in the regulation of cell proliferation,
survival, migration and tumor formation of human pros-
tate carcinoma cells and several melanoma cell lines as
well as in the malignant transformation of human mela-
nocytes [11-13].
These findings which implicate pro-oncogenic effect
of the protein and, furthermore, the fact that Ras was
found is chronically activated in breast carcinoma cells
that lack mutated ras [14], have motivated us to assess
the expression and function of RasGRP3 in breast
derived invasive ductal adenocarcinoma, a malignancy
characterized by a high tendency to produce meta-
static tumors [15]. In the present study, we provide
evidence that expressions of RasGRP3 and its active
form (phosphoRasGRP3) are highly elevated in human
breast cancer samples and that it is also present in
a primary and several metastatic human breast cancer
cell lines. Moreover, we also show that RasGRP3 contrib-
utes to proliferation, survival, chemotherapeutic resistance
and in vivo tumor growth of breast carcinoma-derived
tumor cell lines.Results
RasGRP3 is elevated in human breast derived ductal
adenocarcinoma
First, using Q-PCR (Figure 1A) and Western blot
(Figure 1B), we assessed the expression of the RasGRP3
protein and presumably its active form, phosphoRasGRP3,
in human breast derived ductal adenocarcinoma (Tu)
as well as in normal human breast tissue (Co) sam-
ples. We found that the levels of RasGRP3 and phos-
phoRasGRP3, albeit exhibiting marked inter-individual
variations, were significantly higher in the tumor sam-
ples compared to the controls. In addition, we also
determined the cellular localizations of RasGRP3 and
phosphoRasGRP3 by immunohistochemistry in sections
prepared from the diseased breast tissues. RasGRP3
was localized in the cytoplasm of the cells whereas
the active form exhibited mostly nuclear immunore-
activity (Figure 1C). Human kidney derived samples
(9) served as positive controls (PC) in immunohisto-
chemical experiments.
RasGRP3 is expressed in human breast derived ductal
adenocarcinoma cell lines and involved in the regulation
of growth of MCF7 and T-47D cells
We determined the expression of RasGRP3 in six different
human breast ductal adenocarcinoma derived cell lines,
namely in BT-474, MDA-MB-453, MCF7, SK-BR-3,
T-47D and JIMT-1 cells (the characteristics of the cell
lines and relevant references are shown in Additional
file 1: Table S1). Quantitative PCR and Western blot
analyses confirmed the expression of RasGRP3 in all
cell lines with barely detectable levels in BT-474 and
MDA-MB-453 cells (Figure 2A). For comparison, the
relatively high expression of RasGRP3 in the PC-3 pros-
tate adenocarcinoma derived cell line [12] served as a
positive control in both assays.
To explore the functionality of RasGRP3, namely the
role of the protein in the regulation of proliferation, viabil-
ity, chemotherapeutic resistance and tumorigenesis we
employed the shRNA-interference technique. Namely,
the cellular levels of the protein in MCF7 and T-47D
cells was suppressed by retroviral vectors expressing
shRNAs for RasGRP3 (shRasGRP3) or against a non-
targeting scrambled control (shSCR) to achieve a long
term (stable) suppression (sequences of the shRNA probes
are shown in Additional file 2: Table S2). As determined
by confirmatory Western blot analysis, levels of RasGRP3
could be effectively reduced in both MCF7 and T-47D
cancer cells whereas in cells expressing shSCR significant
modulation of RasGRP3 expression was not observed
(Figure 2B).
We assessed the possible alterations in cellular
functions of the T-47D and MCF7 derived “RasGRP3-
silenced” cells. As revealed by growth curve analysis
Figure 1 RasGRP3 is expressed in human breast derived ductal adenocarcinoma. (A) Q-PCR and (B) Western blot analysis of RasGRP3
and phosphoRasGRP3 expressions in human normal breast (Controls; n = 21) and breast derived ductal adenocarcinoma (Tumors; n = 33)
with various tumor grades (G1-G3) presented according to the molecular grading of human breast derived ductal adenocarcinoma (Luminal A; Luminal
B and HER-2). GAPDH was used as an internal control. The results are representative of three independent experiments for Q-PCR and two independent
experiments for Western blot. Values represent the mean ± SEM. (C) Representative images of RasGRP3- and phosphoRasGRP3-specific immunreactivity
with diaminobenzidine as a chromogen (brown staining) on human normal and breast derived ductal adenocarcinoma sections. Human kidney samples
were included as a positive control (PC) [16]. Nuclei were co-stained by Mayer’s Hematoxylin (blue staining). Preabsorption negative control (NC) was
used. Images were taken at magnifications 20x. The results are representative of four independent experiments.
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assays from days 0–5 of culturing (Figure 2C), down-
regulation of RasGRP3 expression resulted in a significantsuppression of cell growth in both cell lines compared
to the proliferation of cells bearing the non-targeting
shSCR.
Figure 2 RasGRP3 is expressed in human breast derived ductal adenocarcinoma cell lines and represses cell proliferation of both MCF7
and T-47D derived cells. (A) Q-PCR and Western blot analyses of RasGRP3 expression in multiple breast derived ductal adenocarcinoma cell lines.
PC-3 cells were included as a positive control [12]. GAPDH was used as an internal control. The results are representative of three independent
experiments. Values represent the mean ± SEM. Expression of RasGRP3 was inhibited using a specific shRNA (shRasGRP3). A non-targeting scrambled
shRNA (shSCR) was used as a control. (B) Confirmation of the extent of suppression of RasGRP3 expression was determined by Western blotting.
GAPDH was used as an internal control. P indicates the number of subculturing of the RasGRP3 silenced cells. Results are representative of 2
independent experiments. (C) The proliferation of T-47D and MCF7 derived cells was determined using the CyQuant GR cell proliferation assay, with
values normalized to the levels of non-transfected control cells. CyQuant assay was conducted every 24 hours. Values represent the mean ± SEM for 2
independent experiments.
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tumor cells
Furthermore, as determined by flow cytometric analysis
following annexin-V/PI labeling, inhibition of RasGRP3
expression induced apoptosis in MCF7 cells but not in
the T-47D cell line (Figure 3A). To further support the
role of RasGRP3 in the regulation of apoptosis a quantita-
tive fluorimetric MitoProbe™ DilC1 (5) assay was per-
formed. A reduction in the mitochondrial transmembrane
potential is one of the earliest markers of apoptosis [16,17].
MitoProbe DilC1 (5) is a mitochondrial membrane poten-
tial sensitive dye which accumulates in the mitochondria incells with active membrane potential. The staining intensity
decreases in cells with disrupt mitochondrial membrane
potential. We found that RasGRP3 silencing significantly
decreased mitochondrial membrane potential (Figure 3B),
in MCF7 cells, while no significant change was observed in
T-47D cells.
RasGRP3 expression contributes to resistance to
Tamoxifen and Herceptin in the MCF7 and T-47D breast
cancer tumor cells
We also investigated the sensitivities of “RasGRP3-silenced”
MCF7 and T-47D cells to tamoxifen (Tamoxifen) used in
Figure 3 Down-regulation of RasGRP3 expression induces apoptosis in MCF7 derived cells. (A) Representative images of MCF7 and T-47D
derived cells stained with Annexin-V and PI and analyzed by flow cytometry. Data were evaluated with FSC Express softwer and presented in the
percentage of gated cells. Values represent the mean ± SEM for three independent experiments. (B) Assessment of mitochondrial membrane potentials
of MCF7 and T-47D derived cells by fluorimetric DilC1 (5) assay with values normalized to the levels of non-transfected control cells. Values represent the
mean ± SEM for four independent experiments.
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trastuzumab (Herceptin) [18,19]. Down-regulation of
RasGRP3 increased the sensitivity of T-47D cells to the
growth-inhibitory actions of both tamoxifen and trastu-
zumab; i.e. lower concentration induced comparableeffects to those found with higher concentrations on
cells expressing the control shSCR (Figure 4A). Inter-
estingly, suppression of RasGRP3 levels did not affect
the sensitivity of the MCF7 cells to the actions of the
drugs (Figure 4B).
Figure 4 Down-regulation of RasGRP3 increases the sensitivity to tamoxifen and trastuzumab of the T-47D cell line. The indicated MCF7
and T-47D derived cell lines were seeded at a density of 1 x 104 cells/ well and treated with tamoxifen (A) and trastuzumab (B) (tamoxifen: MCF7
cells: 0–200 μM; T-47D cells: 0–100 μM; trastuzumab: both MCF7 and T-47D cells: 0–10 μM). After 72 hours of incubation cell proliferation was
determined using the CyQuant GR cell proliferation assay. The results were normalized to the levels of untreated cells. Values represent the
mean ± SEM of 2 independent experiments.
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tumor formation
To assess furthermore the role of RasGRP3 in in vivo
tumor formation, we employed the SCID mouse xeno-
graft model in which tumors were induced by MCF7
and T-47D cells expressing either shRasGRP3 or shSCR.
In both cell lines, down-regulation of RasGRP3 resulted in
a marked reduction in tumor growth (Additional file 3:
Figure S1 and Additional file 4: Figure S2) as measured by
weight of excised tumors in comparison of those induced
by the shSCR-expressing cells (Figure 5A). These differen-
tial features of the various cells on tumorigenesis were also
proven by immunohistochemical analysis of the expres-
sion of the proliferation marker Ki67. In tumors induced
by RasGRP3-silenced MCF7 cells the number of Ki67
positive cell was significantly less than in the control
shSCR-expressing ones (Figure 5B and Additional file 3:
Figure S1 and Additional file 4: Figure S2). Interestingly,
despite the significantly less tumor size, statistical analysis
did not reveal differences in the Ki67 positive cell number
in the case of the T-47D cells.RasGRP3 is involved in growth factor-induced Akt, ERK1/2
and estrogen receptor activation
Growth factors such as insulin like growth factor-I (IGF-I)
and epidermal growth factor (EGF) represent important
signaling molecules in breast cancer [20,21]. In the final
stage of our experiments, we therefore evaluated the role
of RasGRP3 in modulating the IGF-I and EGF induced
activation of the Ras signaling pathway in both MCF7
and T-47D cells. Cells were treated with IGF-I and EGF
(Figure 6A) as indicated, and the activation of the possibly
most important downstream molecules related to Ras,
ERK 1/2 and Akt kinases were examined by Western blot.
We confirmed that in both cell lines the down-regulation
of RasGRP3 reduced the IGF-I and EGF-induced ERK 1/2
and Akt phosphorylation to the basal level (Figure 6A
and B). Consistent with the central role of Ras signaling
pathway in the activation of estrogen receptor alpha
(ERα), decreasing the level of pERK 1/2 and pAkt led to
a reduction in ERα phosphorylation (Figure 6A).
According to our results MCF7 cells were more sen-
sitive to the growth factors than T-47D cells and the
Figure 5 Suppression of RasGRP3 expression inhibits xenograft tumor growth of both MCF7 and T-47D cells. SCID mice were injected
subcutaneously with 4x106 cells of the indicated MCF7 and T-47D derived cells (n = 4 mice for each group). The animals were sacrificed 12 weeks
after injection, and the tumors were excised, weighted (A) and processed for immunohystochemical analysis. Values represent the mean ± SEM of
four independent experiments. (B) Digitalized images of Ki67-specific immunreactivity (Additional file 3: Figure S1 and Additonal file 4: Figure S2)
obtained on sections prepared from tumors developed by MCF7 and T-47D derived cells were analysed using Image J image analysis softwer. In
every each section the number of cells were counted at 5 randomly placed, equal areas of interest (AOI) and the average of Ki67 imunnopositive
cells of the 5 AOI was defined. Ratios: in T-47D shSCR n = 1213/1098; in T-47D shRasGRP3 n = 1216/1096; in MCF7 shSCR n = 1268/757; in MCF7
shRasGRP3 n = 1112/553. The numbers represent total cell number/Ki67 positive cells ratios. Values represent the mean ± SEM.
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derived “RasGRP3-silenced” cells appearing to respond
to growth factors induced Akt and ERK1/2 down-
regulation earlier. In case of IGF-I application (Additional
file 5: Figure S3) in MCF7 cells, pAKT was affected in
5–30 min, while pAKT is affected only at 30–40 min in
T-47D cells. A marked reduction in ERK ½ activation
can be observed in both cells at 5 and 10 min, which is
still present at 20 and 30 mins in T-47D cells. A de-
crease in ERα phosphorilation can be noticed in MCF7
cells earlier, but the down-regulation is most affected in
T-47D cells. In case of EGF treatment (Additional file 6:
Figure S4) the RasGRP3 mediated down-regulation of Akt
(5–40 min) and ERK ½ (5–20 min) activation was more
effective in MCF7 cells compared to T-47D, in which pAkt
is affected only at 30 min and there is no significant
change in ERK ½ activation. However T-47D cells show a
significant decrease in ERα activation (20–30 min) com-
pared to MCF7 cells, in which pERα is affected only at
20 min. Importantly, down regulation of RasGRP3 had
no measurable effect on basal Akt, ERK1/2 and ERα
phosphorylation and on the total Akt, ERK1/2 and ERα
expression levels.
To validate further a role for RasGRP3 in the modula-
tion of the activation of ERα we examined the effect of
RasGRP3 gene-silencing on the expression of several
ERα-regulated genes [22], namely progesterone receptor
(PGR), cathepsin D (CTSD), cytochrome C (CYCS) and
loricrin (LOR) determined by Q-PCR. Except loricrin
we found a significant reduction in the expression of
these genes in “RasGRP3-silenced” MCF7 and T-47D
cells (Figure 6B). In case of T-47D cells a significant de-
crease was observed in shSCR cells in their cytochrome
C expression compared to the non-treated cells, but in
shRasGRP3 cells this decrease was more expressive.RasGRP3 modulates the expression of IGF-I and EGF
receptors in MCF7 cells
To further clarify the role of RasGRP3 on the activation
of the downstream signaling molecules, the effect of
RasGRP3 inhibition on the expression of upstream IGF-I,
EGF, and Human Epidermal Growth Factor Receptor 2
(HER-2) receptors was investigated (Figure 7). Suppres-
sion of RasGRP3 levels decreased the expression of both
IGF-I and EGF receptors in MCF7 cells, whereas it had no
effect on the receptor expression of T-47D cells. RasGRP3
down-regulation did not modify the expression of HER-2
receptor of the cells.
Discussion
Activation of Ras signaling has long been recognized to
be important for tumorigenesis and progression of can-
cer cells [23,24]. Moreover, it was also suggested that
Ras can be “chronically overactivated” by various up-
stream signaling elements [15] such as e.g. RasGRPs [1].
Previous studies have clearly identified the existence
of RasGRP3 on human Burkitt’s lymphoma, pre-B-cell
leukemia, natural killer-like T-cell leukemia, metastatic
prostate cancer and malignant melanoma [11-13]. Using
Q-PCR and tissue microarray it was proved that RasGRP3
is overexpressed in prostate tumor and melanoma sam-
ples. However, to our best knowledge, we are the first
to describe and quantitatively asses the expression of
RasGRP3 and its active form on human breast ductal
adenocarcinoma cells. Indeed, mutually complementary
Q-PCR, Western blot and immunohistochemical analyses
revealed that the expression of RasGRP3 and the active
phosphoRasGRP3 are elevated in numerous human breast
tumor samples as well as in multiple breast derived ductal
adenocarcinoma cell lines. We have also presented that
the relative level of RasGRP3 and phosphoRasGRP3
Figure 6 Effects of down-regulation of RasGRP3 on the Ras signaling pathway I. RasGRP3 is involved in IGF-I and EGF (A) dependent Akt, ERK
and ERα phosphorilation. RasGRP3 knockdown cell lines created from MCF7 and T-47D cells were treated with or without IGF-I (100 pg/ml) and EGF
(100 pg/ml) as indicated. Akt and phosphorylated Akt, ERK and phosphorylated ERK, ERα and phosphorylated ERα were detected by immunoblotting
of cell lysates. Levels of total Akt, ERK and ERα were used as control. All results were representative of 2 independent experiments. (B) Q-PCR analyses
of ERα-regulated genes, namely progesterone receptor (PGR), cathepsin D (CTSD), cytochrome C (CYCS) and loricrin (LOR). GAPDH was used
as an internal control. The results are representative of three independent experiments. Values represent the mean ± SEM. In case of T-47D cells
loricrin expression *indicates significant difference compared to non-transfected control cells, while #indicates significant difference compared to
scrambled control cells.
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Figure 7 Effects of down-regulation of RasGRP3 on the Ras signaling pathway II. IGF1R, EGFR and HER-2 expressions were detected by Q-PCR
and immunoblotting of RasGRP3 knockdown cell lines created from MCF7 and T-47D cells. GAPDH (Q-PCR) and β actin (Western Blot) were used as
internal controls. The results are representative of three (Q-PCR) or two (Western blot) independent experiments. Values represent the mean ± SEM.
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compared to the normal tissues. We also presented the
expression of RasGRP3 in breast cancer derived cell lines.
Of further importance, we are the first to show that the
subcellular localization pattern of RasGRP3 and its ac-
tive form are markedly different; i.e., RasGRP3 is local-
ized mostly in the cytoplasm whereas phosphoRasGRP3
showed prominent nuclear staining in the breast cancer
cells. RasGRP3 is a high-affinity target for the second mes-
senger diacylglycerol (DAG), its analogues and phorbol-
esters (PMA) regulating their translocation and exchange
factor activity [5,6]. As previously shown RasGRP3 local-
ized mainly in the cytosol [6]. 1,2-dioctanoyl-sn-glycerol
(DOG), a membrane-permeable analogue of DAG and
phorbol ester PMA also induced RasGRP3 redistribution
to the perinuclear region and, to a lesser extent, to the
plasma membrane [6]. The localization to the plasma
membrane is relevant for the activation of Ras [25]. There
are several examples of RasGEFs for Ras that are recruited
to the plasma membrane with activation, such as SOS andRasGRF2 [26,27]. Localization of RasGRP3 in the nucleus
has not been reported before, and its significance is
puzzling. However, forms of H-Ras and Rap1, which
are both potential targets of RasGRP3, have been found
in the nuclei of N-nitrosodiethylamine-induced liver
tumor cells and squamous cell carcinoma lines, respect-
ively [28,29]. In fact, subcellular redistribution in re-
sponse to DAG or its analogs is one of the hallmarks
of activation of RasGRPs, the interaction of the protein
with specific intracellular proteins can also participate
in the translocation events. The role of an adaptor pro-
tein RACK has been shown in the case of a well known
DAG receptor protein kinase C [30]. Dynein light chain
1 (DLC1), a component of the cytoplasmic dynein com-
plex is a novel RasGRP3-interacting protein participating
in the subcellular localization of RasGRP3 [31]. DLC1 is
not only involved in cytoskeleton-mediated motility and
intracellular transport events [32] but was also reported
responsible to regulate the nuclear localization of certain
proteins, namely p53 and brain-enriched protein PMES-2
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tions of ERα [35] and interacts with nuclear transcription
factors in fission yeast [36]. As DLC1 is often overex-
pressed in breast cancer [37] it is interesting to note that
DAG induced DLC1–RasGRP3 interaction may act as a
chaperone for nuclear translocation of RasGRP3 in breast
cancer cells suggesting a mechanistic role for RasGRP3 in
supporting and amplifying growth factor or Ras initiated
cellular responses in breast cancer cells. Obviously further
investigations are needed to support this theory.
Both in vitro and in vivo studies were carried out to
define the exact functional role of RasGRP3 and the
coupled intracellular signaling using RasGRP3 gene si-
lencing in ductal adenocarcinoma derived MCF7 and
T-47D cell lines. Similar to those described in prostate
carcinoma and melanoma [12,13], down-regulation of
RasGRP3 inhibited cell proliferation of both cell lines
and induced apoptosis in MCF7 cells. Among the growth
factor signaling molecules, the major pathway implicated
in supporting survival is the phosphatidylinositide 3-kinase
(PI3K) pathway. Studies indicate that the protective effect
of PI3K is mediated primarily by Akt [38]. In addition, in-
hibition of Akt signalling can induce apoptosis in some
human cancer cell lines [39,40]. Because there are multiple
downstream effectors of Akt, it is not completely clear
how the survival signal is transduced. Given the pivotal
role of BCL-2 family in the regulation of apoptosis previ-
ous reports have shown that Akt delivers antiapoptotic
survival signals by phosphorilating Bad therefore inhibits
apoptosis by maintaining Bcl-xL function and preventing
cytochrome c release from mitochondria. We found the
inhibition of RasGRP3 expression resulted in a decreased
Akt activation downstream from both insulin like growth
factor-I (IGF-I) or epidermal growth factor (EGF) stimula-
tion more intensively in MCF7 cells compared to T-47D
cells therefore we investigated mitochondrial functions
by determining the mitochondrial membrane potential
of T-47D and MCF7 derived cells using a MitoProbe™
DilC1[5] assay. As presented in Figure 3 RasGRP3
down-regulation caused a significant decrease in the
mitochondrial membrane potencial of MCF7 cells but
not in T-47D cells indicating that the protein possibly
through the modulation of Akt activation may lead to
the activation of the mitochondrial pathway of apoptosis.
In addition, suppression of RasGRP3 expression led to
an enhanced sensitivity to the effects of Tamoxifen and
Herceptin of the T-47D cell line (but not of MCF7 cells).
Of further importance, suppression of RasGRP3 expres-
sion reduced xenograft tumor growth and firstly shown
in the case of MCF7 cells decreased Ki67 positivity,
well-known to be important in molecular classification
of breast cancers [41-43]. Collectively, these data strongly
suggest that RasGRP3 indeed has a central role in breast
cancer tumorigenesis.Although RasGRP3 contributes to the signaling of
many phospholipase C activating receptors, the focus of
studies so far has been on its role in immune cell recep-
tor signaling [44-46]. In the case of the breast, expres-
sions of IGF-I receptor and EGF receptor (EGFR or
HER-1) have been reported to be elevated [47-50]. IGF-I
and EGF are potent mitogens for breast cancer cells in-
ducing cellular proliferation and promoting the invasive-
ness and endocrine- or chemotherapeutic resistance of
T-47D and MCF7 breast cancer cells [51-55]. Akt and
ERK1/2 –downstream targets of Ras- play a critical role
in the activation of both cell proliferation and apoptotic
signaling and enhance tumor progression by promoting
cell invasiveness and angiogenesis [56,57]. Although it
was confirmed that modulation of RasGRP3 contributes
to Akt and ERK1/2 activation in prostate cancer and
melanoma cells [12,13], here we are the first to demon-
strate that RasGRP3 contributed to signaling downstream
of IGF-I and EGF in the MCF7 and T-47D cells by
modifying the level of IGF-I and EGF induced phos-
phorylation of Akt and ERK 1/2. Namely, down-regulation
of RasGRP3 decreased the level of phosphorylated Akt and
ERK 1/2 induced by both IGF-I or EGF stimulation in both
cell lines, but with a different activation profile. MCF7
derived “RasGRP3-silenced” cells appearing to respond
to growth factors induced Akt and ERK1/2 down-
regulation earlier and more effectively. The effects of
upstream growth factors are mediated in part through
RasGRP3 in breast cancer cells; as such these results
help fill out the gaps of our current knowledge of the
breast cancer signaling network (Figure 8). Furthermore,
RasGRP3 not only caused the down regulation of IGF-I
and EGF induced downstream signaling, but also de-
creased the expression of IGF-I and EGF receptors in
MCF7 cells. The effects of RasGRP3 on Akt and ERK
1/2 phosphorylation in both T-47D and MCF7 cells are
consistent with our demonstration that RasGRP3 is
contributing to Ras activation and likewise support the
effects we observed on cell proliferation, chemothera-
peutic resistance and tumorigenesis. Since it was previ-
ously shown that RasGRP3 contributes to carboplatin
sensitivity of PC-3 and DU-145 prostate carcinoma cells
[12], these results may also be prominently important in
the context of endocrine- or chemotherapeutic resistance
of breast cancer cells as well.
The primary treatment of ER positive primary and ad-
vanced breast cancer is the non-steroidal anti-estrogen
tamoxifen, while HER-2/neu positive tumor treatment is
focused on trastuzumab, a monoclonal antibody against
the HER-2 receptor. Many ER positive tumors are de novo
resistant to tamoxifen without any prior exposure; further-
more, many of the tumors that initially respond to tamoxi-
fen can aquire resistance during and after tamoxifen
therapy which presents a major clinical problem [58-61].
Figure 8 A schematic overview presenting the role of RasGRP3 in mediating the Ras signaling pathways in breast carcinoma cells. The
signaling of growth factors (such as IGF-I and EGF) through downstream signaling molecules to ERα is mediated by RasGRP3. Inhibition of the
Ras signaling pathway at the RasGRP3 level bears the potential to suppress downstream activation and ligand independent activation of ERα
resulting in a decreased proliferation and chemotherapeutic resistance. Abbreviations: IGFR: insulin-like growth factor-I receptor; EGFR: epidermal
growth factor receptor; HER-2: Human Epidermal Growth Factor Receptor 2; IGF-I: insulin-like growth factor-I; EGF: epidermal growth factor; PLC:
phospholipase C; DAG: diacylglycerol; C1: C1 domain; RasGRP3: Ras guanil nucleotid releasing protein 3; GTP: guanosine triphosphate; Ras: H-Ras
or R-Ras; Raf: raf kinase; MEK and ERK 1/2: mitogen-activated protein kinases; PI3K: phosphoinositide 3-kinase; Akt: Akt kinase; ER: estrogen receptor
alpha; P: phosphate group.
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have been suggested to explain this resistance, including
ligand independent phosphomodification of ERα and an
increased crosstalk between ERα and HER-2 receptor
[62-64]. Ligand-independent activation of ERα has been
reported in response to EGF or IGF-I through ERK1/2, by
stimulating the phosphorylation of Ser 118 on the ERα, a
clear predictive marker for response to tamoxifen [65,66].
Studies have shown that clinical resistance to tamoxifen
can also be associated with EGFR and HER-2 upregulation
[67,68]. The tamoxifen resistant MCF7 cell line demon-
strates increased EGFR/HER-2/MAPK signaling activity;
furthermore, it also shows high levels of phosphorylation
of ERα at Ser 118 and enhanced sensitivity to the growth
inhibitory actions of EGFR and the HER-2 monoclonal
antibody trastuzumab [69]. Taking into account that
RasGRP3 is able to regulate the activity of ERK 1/2
and Akt kinases as well as the expression of EGFR, we
are the first to investigate the role of RasGRP3 in the
development of tamoxifen resistance. Here, we firstly
demonstrated the role of RasGRP3 in decreasing the
phosphorylation of ERα at Ser 118 through the down-
regulation of Akt and ERK 1/2 pathways both in T-47D
and MCF7 cells. MCF7 cell line demonstrates higher
levels of phosphorylation of ERα at Ser 118 compared to
T-47D cells. It can be supposed that in T-47D cells bydecreasing ERα transactivation RasGRP3 down-regulation
contributed to an increased tamoxifen sensitivity. How-
ever, decreasing of ERα activation in MCF7 cells (other-
wise more affected cells to EGF and IGF-I treatment) had
no effect on tamoxifen sensitivity. Furthermore we dem-
onstrated the role of RasGRP3 in the modulation of
the activation of ERα by decreasing the expression of
ERα-regulated genes [22], progesterone receptor (PGR),
cathepsin D (CTSD) and cytochrome C (CYCS).
Besides tamoxifen we are the first to investigate the
role of RasGRP3 in regulation of trastuzumab sensitivity
of T-47D and MCF7 cells. The potential mechanisms of
resistance to trastuzumab not only involves steric effects,
such as the structural mutation in HER2 protein, but the
alternative elevations of other tyrosine kinase receptors,
such as insulin-like growth factor receptor (IGFIR), or
the intracellular alterations in growth factor downstream
signaling like constitutive activity of PI3K/Akt pathway
[70].These findings imply that cancer cells, by utilizing
other growth factor signaling, can compensate for the in-
hibition of HER2 signaling mediated by trastuzumab. A
promising target whose aberrant expression may confer
resistance to trastuzumab is the IGF-IR [71] the ectopic
expression of IGF-1R drives trastuzumab-sensitive SKBR3
and MCF-7/HER2-18 cells to resistant to the therapy. Al-
though the down regulation of RasGRP3 had no effect on
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creasing the level of phosphorylated Akt and ERK 1/2 in-
duced by IGF-I or EGF stimulation can contribute to an
increased sensitivity of the cells against trastuzumab. Since
the inhibition of RasGRP3 expression not only caused the
down regulation of IGF-I and EGF induced downstream
signaling, but also significantly decreased the expression
of IGF-I and EGF receptors in MCF7 cells we found it
interesting to investigate the role of these receptors in
possible role of trastuzumab resistance of MCF7 cells,
expressing low amount of HER-2 receptor. According
to our results the RasGRP3 gene-silencing and IGFIR
down-regulation had no effect on the trastuzumab sen-
sitivity of MCF7 cells.
Collectively, our current findings – i.e. the identifica-
tion of RasGRP3 as an additional important signaling
element together with the evidence for its elevated ex-
pression in a subpopulation of breast tumors – identify
RasGRP3 as a novel, promising target molecule for
pathway directed chemotherapy in the supportive treat-
ment and diagnosis of ductal adenocarcinoma of hu-
man breast.
Conclusions
Breast cancer is the leading cause of cancer death among
females. Several studies have identified the expression of
RasGRP3 on different malignant cancer types, but in this
study we show for the first time that RasGRP3 is overex-
pressed in human breast cancer samples as well as in
multiple breast cancer derived cell lines. Our in vitro
and in vivo data, together with that of others [12,13]
have shown the importance of RasGRP3 function in the
regulation of proliferation, survival, chemotherapeutic
sensitivity and tumorigenesis of breast carcinoma cells.
We have further demonstrated that RasGRP3 contrib-
uted to Ras-related signaling downstream of IGF-I and
EGF growth factors by modifying the level of IGF-I and
EGF induced activation of Akt, ERK ½ kinases, estrogen
receptor α and the expression of IGF-I and EGF growth
factor receptors. Collectively, these data suggest that the
overexpression of the protein might be a relatively early
step in the process of tumorigenesis; hence, the deter-
mination of RasGRP3 levels in breast cancer tissues may
hold promise for the benefits of early diagnosis and may
offer suitable target for treatment of breast tumors.
Materials and methods
Human tissues
The human study was approved by the Institutional Re-
search Ethics Committee of the University of Debrecen,
Debrecen, Hungary and by various authorities of the
Hungarian Government. All patients provided written
informed consent for participation in the study and pub-
lication of the results. Twenty-one normal adult (healthy)breast tissue samples and 33 breast derived ductal adeno-
carcinoma samples (grade I-III) were obtained as part of
routine diagnosis from surgical specimen. Samples were
verified by histopathological evaluations by expert pathol-
ogists. Neither the control patients nor the diseased pa-
tients had history of previous or contemporary breast
malignancies.
Human tissue sample preparation
The tumor samples were divided into two parts. One part
of the samples was processed to obtain formalin-fixed,
paraffin-embedded sections which were subjected to rou-
tine haematoxylin-eosin staining-based grading according
to the Nottingham scale (the pathohistological diagnosis
of the individual tumors is detailed in Figure 1A and B).
The second part was frozen in liquid nitrogen and proc-
essed for Q-PCR and Western blot analysis (see below).
Antibodies for Western blotting and immunolabeling
Throughout the experiments, the following primary
antibodies were used: RasGRP3 and phospho-RasGRP3
(Thr133); p44/42 MAP kinase (ERK 1/2) and phospho-
p44/42 MAP kinase (phospho-ERK 1/2); Akt and phospho-
Akt (Ser473) antibodies for Western blot experiments
were obtained from Cell Signaling Technology (Beverly,
MA). Anti-RasGRP3 antibody for immunohystochemistry
was purchased from Abcam (Cambridge, UK). Ki67 anti-
body was obtained from DAKO (Glostrup, Denmark).
Actin β, ERα, p-ERα (Ser 118) and HER-2 antibodies
were purchased from Sigma-Aldrich (St. Louis, MO). IGF-
IR and EGFR antibodies were obtained from Santa Cruz
Biotechnology (Dallas, TX). Glyceraldehyde 3-phosphate
dehydrogenase (GAPDH) antibody was obtained from
Novus Biologicals (Cambridge, UK). Appropriate second-
ary antibodies were purchased from Bio-Rad Laboratories
(Hercules, CA).
Immunohistochemistry
The expression of RasGRP3 and phosphoRasGRP3 were
determined by a horseradish-peroxidase (HRP) based
method with diaminobenzidine (DAB) as a chromogene.
Tissues were fixed overnight in 4% paraformaldehyde,
followed by paraffin infiltration and embedding. Sections
were de-waxed and subjected to heat-induced epitope
retrieval in 10 mM citrate buffer (pH 6.0) at 750 W in
microwave oven for 10 min prior to treatment with 3%
hydrogen peroxide in absolute methanol. Sections were
then incubated in blocking buffer containing 0.6%
Triton X-100 and 1% bovine serum albumin (all from
Sigma-Aldrich) for 30 min and probed with the appropri-
ate primary antibodies. Sections were then stained for
30 minutes with the appropriate horseradish peroxidase-
labeled polymer conjugated secondary antibodies. Immu-
noreactions were visualized using DAB substrate (EnVision
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terstained by Mayer’s hematoxylin (Sigma-Aldrich) and
cover-slipped for microscopic examination. To assess spe-
cificity of the immunostaining antibodies were either omit-
ted from the procedure or were pre-absorbed by control
blocking peptides provided (along with appropriate pro-
tocols) by the manufacturers. Images of RasGRP3 and
phospho-RasGRP3-labeled sections were photographed at
20x magnification (see Figure 1C). Immunohistochemical
images were captured and digitalized using an RT Spot
Colour CCD camera (Diagnostic Instruments Inc., Ster-
ling Heights, MI) integrated on a Nikon Eclipse 600 fluor-
escence and light microscope (Nikon, Tokyo, Japan).
Cell culturing
In this study, we employed six different breast derived
ductal adenocarcinoma cell lines (BT-474, MDA-MB-453,
MCF7, SK-BR-3, JIMT-1, T-47D) and, as a positive control
[12], a prostate derived carcinoma cell line (PC-3). Human
breast cancer cell lines were kind gifts from Dr. Péter
Nagy at the University of Debrecen, Medical and Health
Science Center Faculty of Medicine, Department of Bio-
physics and Cell Biology, Debrecen, Hungary. PC-3 cell
line was kindly provided by the Laboratory for Cancer
Biology and Genetics, National Cancer Institute, National
Institute of Health, Bethesda, Maryland, USA. PC-3, BT-
474 and T-47D cells were maintained in RPMI-1640
Medium (Sigma-Aldrich), MCF7 cells were maintained
in Eagle's Minimum Essential Medium (MEM) (Sigma-
Aldrich), JIMT-1 cells were maintained in Dulbecco’s
Modified Eagle Medium (DMEM)/Ham’s F12 Medium
(Sigma-Aldrich), SK-BR-3 cells were maintained in
Dulbecco’s Modified Eagle Medium (DMEM) and MDA-
MB-453 cells were maintained in Leibovitz’s 15 Medium
(Invitrogen). All medium were supplemented with 10%
(v/v) fetal bovine serum (FBS, Invitrogen, Paisley, UK),
2 mM Glutamine (Sigma-Aldrich), 50 U/ml penicillin and
50 μg/ml streptomycin (both from TEVA, Debrecen,
Hungary). In addition, medium for T47-D cells was sup-
plemented with 0.2 U/ml bovine insulin (Sigma-Aldrich),
medium for MCF7 cells was supplemented with 0.01 mg/
ml bovine insulin and medium for JIMT-1 cells was
supplemented with 60 U/l bovine insulin. Medium was
changed every other day and cells were sub-cultured at
80% confluence at 37°C in a humidified atmosphere
with 5% CO2.
Western blotting
Tissues and cells were homogenized in lysis buffer (20 mM
Tris-Cl, 5 mM EGTA, pH 7.5 and protease inhibitor cock-
tail all from Sigma-Aldrich) and the protein content of
samples was measured by the BCA protein assay kit
(Pierce, Rockford, IL). The lysates containing 20 μg total
protein (except for RasGRP3 and phosphoRasGRP3immunoblotting where 60 μg total protein was used) were
separated by electrophoresis on 10% SDS-polyacrylamide
gels (Invitrogen) and transferred onto BioBond nitro-
cellulose membranes (Whatman, Maidstone, UK). After
the membranes were blocked and labeled with the ap-
propriate primary and secondary antibodies, the immu-
noreactive bands were visualized by SuperSignal West
Femto Chemiluminescent Substrate-enhanced chemilu-
minescence (Pierce, Rockford, IL) using a Gel Logic
1500 Imaging System (Kodak, Tokyo, Japan). To assess
equal loading (and to obtain an endogenous control),
membranes were re-probed with a GAPDH or actin β
antibody followed by a similar visualization procedure
as described above.
Quantitative real-time PCR (Q-PCR)
Quantitative real-time PCR was performed on an ABI
Prism 7000 sequence detection system (Applied Biosys-
tems, Foster City, CA) by using the 5′ nuclease assay, as
we have previously described [72]. Total RNA was ex-
tracted with TRIzol reagent (Invitrogen) according to
manufacturer's protocol. One microgram of total RNA
were then reverse transcribed into cDNA by using High
Capacity cDNA Reverse Transcription Kit (Applied Bio-
systems) according to the manufacturer’s instructions.
PCR amplification was performed by using the TaqMan
primers and probes (Assay IDs: Hs 00964396_m1 for hu-
man RasGRP3; Hs 01076078_m1 for human EGFR; Hs
00609566_m1 for human IGF1R; Hs 01001580_m1 for
human HER-2/ERBB2; Hs 01894962_s1 for human LOR;
Hs01588974_g1 for human CYCS; Hs 00157205_m1 for
humanCTSD ans Hs 01556702 for human PGR) using the
TaqMan Universal PCR Master Mix Protocol (Applied
Biosystems). The threshold cycle (Ct) of RasGRP3 was
determined and normalized to that of human GAPDH
(Assay ID: Hs 03929097_g1) to obtain a ΔCt value
(CtGAPDH-Ctappropriate protein) from each sample. The
Q-PCR was performed in triplicate.
shRNA construct for RasGRP3
Gene knockdown was achieved by stable transduction
with a retroviral-based pRNA-H1.1/Retro Vector system
(GenScript, Piscataway, NJ) containing previously de-
scribed RasGRP3-specific hairpin RNA (shRasGRP3; se-
quence listed in Additional file 1: Table S1) os scrambled
control sequence (shSCR; sequence listed in Additional
file 1: Table S1) which has no specific targets in mam-
malian cells [12,13]. The designed single-stranded oligo-
nucleotides were synthesized, annealed, inserted into the
pRNA-H1.1/Retro vector by GenScript. All constructs were
verified by DNA sequencing. The retroviral constructs were
then produced and titered by following the manufacturer’s
instructions (Clontech, CA). The two host cell lines, MCF7
and T-47D were infected with each retroviral supernatant
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3 weeks. Studies were carried out on the clone selected,
antibiotic-resistant cells. Efficiency of the suppression of
RasGRP3 expression was determined using Western blot-
ting as described above.
Cell proliferation assay
The degree of cellular growth was determined by meas-
uring the DNA content of cells using CyQUANT GR
Cell Proliferation Assay Kit (Invitrogen) according to the
manufacturer's protocol. MCF7 and T-47D cells (10 000
cells per well) were cultured in 96-well black-well/clear-
bottom plates (Greiner Bio-One, Baden-Württemberg,
Germany) in quadruplicates and were growth for 5 days.
The assay was performed each day. Supernatants were
removed by blotting on paper towels, and the plates
were subsequently frozen at −70°C. The plates were then
thawed at room temperature, and 200 μl of CyQUANT
GR dye/cell lysis buffer mixture was added to each well.
After 5 minutes of incubation, fluorescence signals were
quantitated on a Fluorescence Imaging Plate Reader
FlexStationIII (FLIPR, Molecular Devices, CA) at an exci-
tation wavelength of 485 nm and an emission wave-
length of 530 nm [73].
The CyQUANT assay was employed to assess the che-
motherapeutic sensitivity of the cells. For this, MCF7
and T-47D cells were plated in 96-well black-well/clear-
bottom plates (Greiner Bio-One) in quadruplicates at a
density of 104 cells/well. After overnight culturing, various
concentrations of chemotherapeutics, i.e. trastuzumab
(F.Hoffmann-LaRoche Ltd., Switzerland) and tamoxifen
(Sigma-Aldrich) were administered for 72 h. After the
indicated time, cells were suspended in 200 μl CyQuant
GR cell proliferation assay binding solution and ana-
lyzed as described above.
Detection of apoptotic and necrotic cells
Cells were harvested, washed once in ice-cold Dulbecco’s
phosphate buffered saline (DPBS), and re-suspended in
0.5 ml DPBS. Annexin-V (Invitrogen) was added to a
final concentration of 1 μM and the cells were incubated
for 20 min at 4°C in the dark. Propidium iodide (PI)
(Invitrogen) was then added at a 5 μg/ml final concen-
tration 10 minutes before analysis by flow cytometry using
the FACScan system (BD Biosciences, Oxford, UK). Data
were analyzed with FSC Express software (De Novo
Softwer, CA).
Mitochondrial membrane potential was also assessed
by MitoProbe DilC1(5) Assay Kit (Invitrogen). T-47D
and MCF7 derived cells (5,000 cells/well) were cultured
in 96-well black-well/clear-bottom plates in quadrupli-
cate. After removal of supernatants, cells were incubated
with DilC1(5) working solution –prepared according to
the manufacturer’s instructions- and the fluorescenceof DilC1(5) was measured at 630-nm excitation and
670-nm emission wavelengths using Fluorescence Imaging
Plate Reader FlexStationIII.
Xenograft experiments
Severe combined immunodeficiency (SCID) mice of
12–13 weeks of age were provided by Dr. György Vereb
(University of Debrecen, Medical and Health Science
Center Faculty of Medicine, Department of Biophysics and
Cell Biology, Debrecen, Hungary). The mice were bred
and maintained in the animal facility of the Department of
Dermatology (University of Debrecen, Medical and Health
Science Center Faculty of Medicine) in accordance with
the animal-welfare ordinance. The studies were performed
under the current regulations and standards of the Institu-
tional Research Ethics Committee of the University of
Debrecen, Debrecen, Hungary. Cells were harvested by
trypsinization and washed twice with DPBS. Cell pellets
(4× 106 cells) were re-suspended in 0.1 ml appropriate
medium and 0.1 ml Matrigel (BD Biosciences) and
injected in a single subcutaneously site on the right flank
of the mice (0.2 ml/injection). The animals were sacrificed
after 8 weeks and the tumors were excised, weighed and
placed in 4% paraformaldehyde for immunohistochemical
analysis. To evaluate proliferation Ki67-specific labeling
was performed according to the manufacturer instruc-
tions (see Figure 5B and Additional file 3: Figure S1
and Additional file 4: Figure S2). The histopathological
evaluations of the xenograft tumor derived sections were
verified by expert pathologists.
Image analysis
Immunohistochemical images were captured and digita-
lized using an RT Spot Colour CCD camera (Diagnostic
Instruments Inc.) integrated on a Nikon Eclipse 600
fluorescence and light microscope (Nikon). Digitalized
images were then analyzed using Image J (NIH, Bethesda,
MD) image analysis software. The number of cells were
counted at five randomly placed, equal areas of interest
(AOI) and the average of Ki67 imunnopositive cells of the
5 AOI was defined.
Statistical analysis
The data are expressed as mean +/−SEM. Significance
differences were assessed by a two-tailed un-paired t-test
(p < 0.05 values were defined as significance). The symbol
of * indicates significant difference compared to scrambled
control cells, except if it is indicated otherwise.
Additional files
Additional file 1: Table S1. Characteristics of the cell lines used in the
study.
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non-targeting scrambled control.
Additional file 3: Figure S1. Inhibition of RasGRP3 expression inhibites
xenograft tumor growth of T-47D cells. (A) Representative images of T-47D
xenografts (n=4) injected with shSCR or shRasGRP3 derived cells taken
during dissection. Black arrows indicate the tumors. Scale bar: 10 mm.
(B) Haematoxylin-eosin stained representative images of the developed
shSCR or shRasGRP3 xenograft tumors. T-47D cells derived tumors showed
„ Pushing-type” of growth reflected in an infiltrative and expansive
growth pattern with mechanical pressure to the sorrounded tissues.
Necrotic areas (NeA) frequently developed in these tumors. Scale bar:
200 μm. (C) Representative images of Ki67-specific immunoreactivity with
diaminobenzidine as a chromogen (brown staining) on sections prepared
from tumors developed by shSCR or shRasGRP3 derived cells. Nuclei were
co-stained by Mayer’s Hematoxylin (blue staining). Scale bar: 100 μm.
Additional file 4: Figure S2. Inhibition of RasGRP3 expression inhibites
xenograft tumor growth of MCF7 cells. (A) Representative images of
MCF7 xenografts (n=4) injected with shSCR or shRasGRP3 derived cells
taken during dissection. Black arrows indicate the tumors. Scale bar: 10 mm.
(B) Haematoxylin-eosin stained representative images of the developed
shSCR or shRasGRP3 xenograft tumors. Compared to T-47D cells MCF7
derived tumors are composed of more differentiated tumor tissue with less
infiltrative nature. In these tumors no large necrotic areas were present.
Scale bar : 200 μm. (C) Representative images of Ki67-specific immunoreactivity
with diaminobenzidine as a chromogen (brown staining) on sections
prepared from tumors developed by shSCR or shRasGRP3 derived cells.
Nuclei were co-stained by Mayer’s Hematoxylin (blue staining). Scale
bar: 100 μm.
Additional file 5: Figure S3. Effects of down-regulation of RasGRP3 on
the Ras signaling pathway I. RasGRP3 is involved in IGF-I dependent Akt,
ERK and ERα activation. RasGRP3 knockdown cell lines created from
T-47D (A) and MCF7 (B) cells were treated with or without IGF-I (100 pg/
ml) as indicated. Akt and phosphorylated Akt, ERK and phosphorylated
ERK, ERα and phosphorylated ERα were detected by immunoblotting of
cell lysates. Levels of total Akt, ERK and ERα were used as control. All
results were representative of 2 independent experiments.
Additional file 6: Figure S4. Effects of down-regulation of RasGRP3 on
the Ras signaling pathway II. RasGRP3 is involved in EGF dependent Akt,
ERK and ERα activation. RasGRP3 knockdown cell lines created from T-47D
(A) and MCF7 (B) cells were treated with or without EGF (100 pg/ml) as
indicated. Akt and phosphorylated Akt, ERK and phosphorylated ERK,
ERα and phosphorylated ERα were detected by immunoblotting of cell
lysates. Levels of total Akt, ERK and ERα were used as control. All results
were representative of 2 independent experiments.
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